The CALRdel52/ERK/Sp1 pathway, which is responsible for TGF-β1 production by CALRdel52 cells, has been identified as a potential therapeutic target for mitigating the immunosuppressive effects of TGF-β in CALRdel52 MPN. The gene discussed is TGFB1; the disease is myeloproliferative disorder.